Table of Contents
STUDY GOALS AND OBJECTIVES
This report, Therapies and Diagnostics for Ovarian Cancer, provides an overview of the current and potential global market for ovarian cancer and treatments and testing technologies. The report provides comprehensive information on ovarian cancer and highlights treatment guidelines. It identifies and analyses the key trends driving the global ovarian cancer therapeutics market. The key objective is to present a comprehensive analysis of the current ovarian cancer technology and utilization of the various therapeutic and diagnostic modalities. The report’s focus is on treatment strategies and drugs, chemotherapy and other treatment modalities and testing and screening methods in regard to ovarian disorders. Important trends in the field, research, new developments and sales forecasts by treatment and screening categories from 2013 through 2018 are provided in this report. Issues and trends addressed in this report are based on information from industry sources, regulatory and healthcare policies, demographics and other factors that directly affect the ovarian cancer market.
It also focuses on the treatment usage patterns in the global ovarian cancer therapeutics market, competitive landscape and the emerging players, pipeline products. The report also details opportunity for future players.
REASONS FOR DOING THIS STUDY
This study was conducted to provide detailed information regarding screening, testing and treatment options for ovarian disorders and cancer. There is an increasing need for new and innovative technologies. This industry is experiencing tremendous growth. Many diseases discussed in this report are global issues, and a need exists for newer diagnostic and treatment strategies. This study looks at most types of diagnostic and treatment strategies for the clinical management of ovarian disorders and related cancers.
This BCC market research report will increase the awareness of current and emerging drugs and technologies for ovarian cancers, including therapeutics, chemotherapy and surgical therapy.
This report is an exhaustive study on the global ovarian cancer market, with important statistics and analysis on existing drugs and diagnostic technologies, latest trends, market structure, market size, key drug segments and trends in technology. This study contributes to the areas of market growth in ovarian cancer prevention and treatment strategies from the point of view of manufacturers, product suppliers, healthcare providers and consumers of hematological disorder and cancer products and services. This study will be of interest largely to the pharmaceutical and biotechnology industries, but will also benefit clinics, hospitals and research institutes. This report may also prove crucial for investment firms in the concerned sector. The report shows tests currently being used for ovarian disorders and cancer diagnosis and prognosis, new developments, spending trends and revenue prospects for these technologies. The report provides market data for 2012 to 2018 and also covers commercial prospects, ovarian cancer diagnostic assays, current tests in use and the future of all these areas of interest.
SCOPE OF THE STUDY
The scope of this study is testing and screening technology and also therapeutics markets for ovarian cancers. The report also includes the regulatory environment, current technologies, new technologies, ovarian cancer incidence, market projections and market share along with latest trends and new developments.
Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, industry news and developments, and paid and free databases. The base year of the report is 2012, with forecast data provided through 2018. Historical, base year and forecast data are provided for each market segment covered in this report. The report provides a comprehensive review of prostate cancer, incidence and development of the disease, drugs currently being used and diagnostic technologies. The report also reviews technological developments, product innovations/introductions and recent strategic industry activity of major players across various product categories. Growth rates, global incidence and projections are determined through a compilation of data including past trends, future trends, demographics, incidence, mortality, products in R&D and current product growth. Forecasts and projections were based on estimates such as the current trends, potential users, mergers and acquisitions, and market trends.
A comprehensive and exhaustive search of the literature on ovarian disorders and cancers, marketed products, global incidence and drug developments was conducted. These secondary sources included scientific journals and articles, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports and other publications. A patent search and analysis were also conducted. Some informal interviews were also conducted with experts and personnel in this area at biotech and pharmaceutical companies. Other resources included academics, technology and consulting companies.
Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of products, such as the pharmaceutical and biotechnical industries and research institutes. Data were gathered from various industry sources. BCC spoke with officials within the industry and consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.
ABOUT THE AUTHOR
Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification including IND enabling studies and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early startups to fulfill operational obligations while minimizing overall operational cost and burden.
This report provides:
• An overview of the global market for diagnostics and therapies for ovarian cancer, the fifth most common cancer in American women and the fourth most common cause of female cancer deaths.
• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
• A breakdown of the markets by diagnostics and test, surgery, radiation therapy, and drug therapy.
• Discussion of ovarian cancer biology.
• Delineation of drugs approved to treat the disease, including chemotherapeutic and immunotherapeutic.
• Evaluation of the patent landscape.
• Comprehensive profiles of key companies.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
The global market for ovarian cancer diagnostics and therapeutics accounted for USD 1,106 million in 2015 and is expected to grow at a CAGR of 10-16% by 2020. Ovarian cancer is caused by an uncontrollable ...
The North American market for ovarian cancer diagnostics and therapeutics accounted for USD 479 million in 2015 and is expected to grow at a CAGR of 10-16% by 2020. Ovarian cancer is caused by an uncontrollable ...
The Latin American market for ovarian cancer diagnostics and therapeutics accounted for USD 44 million in 2015 and is anticipated to grow at a CAGR of 10-16% till 2020. Ovarian cancer is caused by an uncontrollable ...